PPARG and melanoma: Similarly, treatment of melanoma cells expressing non-specific shRNA with rosiglitazone, a PPARγ agonist [45], also increased PPAR-responsive firefly-luciferase reporter activity compared with vehicle-treated cells expressing non-specific shRNA (Figure 5F).